Sentiment Trading

Xencor Inc. has announced promising early-stage results for its lead investigational product, XmAb819, a bispecific antibody therapy that achieved a 25% objective response rate in patients with advanced clear cell renal cell carcinoma.

Xencor, Inc. is a biotechnology company pioneering the development of antibody and protein therapeutics to combat cancer and autoimmune inflammation, with a mission to transform lives and a promising future ahead.

Xencor Inc. has advanced its treatment for ulcerative colitis into a Phase 2b clinical study, with positive trial results for its treatment targeting inflammatory bowel disease, positioning the company at the forefront of addressing unmet medical needs.